CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on April 26, 2006
Clin J Am Soc Nephrol 1: 718-722, 2006
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01711105
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01711105v1
1/4/718    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preddie, D. C.
Right arrow Articles by Appel, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preddie, D. C.
Right arrow Articles by Appel, G. B.
Related Collections
Right arrowRelated Article

Clinical Nephrology

Mycophenolate Mofetil for the Treatment of Interstitial Nephritis

Dean C. Preddie*, Glen S. Markowitz{dagger}, Jai Radhakrishnan*, Thomas L. Nickolas*, Vivette D. D’Agati{dagger}, Joshua A. Schwimmer*,{ddagger}, Mark Gardenswartz{ddagger}, Raquel Rosen§, and Gerald B. Appel*

* Department of Medicine/Division of Nephrology and {dagger} Department of Pathology, Columbia University College of Physicians & Surgeons, and {ddagger} Department of Medicine/Division of Nephrology, Lenox Hill Hospital, New York, and § Department of Medicine/Division of Nephrology, Mary Imogene Bassett Hospital, Cooperstown, New York

Address correspondence to: Dr. Dean C. Preddie, Department of Medicine/Division of Nephrology, Columbia University College of Physicians & Surgeons, 622 West 168th Street, PH4-124, New York, NY 10032. Phone: 212-305-3273; Fax: 212-305-6692; E-mail: dcp2014{at}columbia.edu

Acute interstitial nephritis (AIN) is a clinicopathologic entity that is characterized by acute renal failure and renal biopsy findings of interstitial inflammation and tubulitis. There are multiple causes of AIN, the majority of which appear to respond to immunosuppressive therapy. Corticosteroids are the mainstay of treatment for AIN, but many patients are refractory to or intolerant of treatment or are unable to discontinue therapy without clinical relapse. Herein are reported eight cases of steroid-resistant, biopsy-proven AIN that were treated successfully with mycophenolate mofetil (MMF) at one institution. Patients had a mean decline in serum creatinine from 2.3 to 1.6 mg/dl over a mean of 24.3 mo of treatment. Six of the eight patients had a decline in serum creatinine of at least 0.3 mg/dl, and the remaining two patients had stable renal function during the treatment period. At most recent follow-up, five of the eight patients successfully have discontinued treatment with MMF for a mean of 6.4 mo. MMF was well tolerated by all patients. It is concluded that MMF is a useful therapeutic option for steroid-resistant AIN and may be considered as potential first-line therapy in select populations.


Related Article

Is Mycophenolate Mofetil a New Treatment Option in Acute Interstitial Nephritis?
Bernardo Rodríguez-Iturbe
Clin. J. Am. Soc. Nephrol. 2006 1: 609-610. [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Nephrology.